Humacyte to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company, announced its participation in two upcoming investor conferences in March 2022. Laura Niklason, CEO, and Dale Sander, CFO, will represent the company. They will present at Cowen’s 42nd Annual Health Care Conference on March 8 at 2:10 p.m. EST and Oppenheimer’s 32nd Annual Healthcare Conference on March 16 at 12:40 p.m. EDT. Both presentations will be accessible for replay for 30 days. Humacyte is known for developing bioengineered human tissues aimed at improving patient outcomes.

DURHAM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.

Cowen’s 42nd Annual Health Care Conference (March 7-9, 2022)
Format:	Virtual Fireside Chat
Date:	Tuesday, March 8, 2022
Time:	2:10 – 2:20 p.m. EST
Oppenheimer’s 32nd Annual Healthcare Conference (March 15-16, 2022)
Format:	Virtual Corporate Presentation
Date:	Wednesday, March 16, 2022
Time:	12:40 – 1:10 p.m. EDT

The webcasts will be available for replay for at least 30 days following the presentations at https://investors.humacyte.com/news-events/events-and-presentations.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
media@humacyte.com

FAQ

When will Humacyte participate in investor conferences in March 2022?

Humacyte will participate in Cowen’s 42nd Annual Health Care Conference on March 8 and Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022.

What are the dates and times for Humacyte's presentations in March 2022?

Humacyte's Cowen presentation is on March 8 at 2:10 p.m. EST, and the Oppenheimer presentation is on March 16 at 12:40 p.m. EDT.

How can I access the webcasts of Humacyte's investor presentations?

The webcasts of Humacyte's presentations will be available for replay for at least 30 days on their investor website.

What type of technology is Humacyte developing?

Humacyte is developing bioengineered human tissues, specifically acellular tissues designed for various medical applications.

What is the focus of Humacyte's clinical trials?

Humacyte's clinical trials are focused on human acellular vessels for treating vascular conditions such as trauma repair and hemodialysis access.